About this trial
This is an international, multi-center, randomised, open-label, superiority phase III trial of elacestrant vs standard endocrine therapy. During the screening ctDNA phase, patients will be tested at different timepoints to detect the presence of ctDNA in their blood. Patients who are found to be ctDNA-positive and have no evidence of distant metastasis or locoregional recurrence, will be randomised 1:1 between standard endocrine treatments (the same they were receiving when tested ctDNA positive) versus elacestrant, provided they meet all eligibility criteria.
Patient Profile
For patients with ER+/HER2- early-stage breast cancer with ctDNA relapse.
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | TREAT ctDNA study |
|---|---|
| Number: | 23-06 |
| Full Title: | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse |
| Principal Investigator: | Prof. Cathy Kelly |
|---|---|
| Type: | Collaborative |
| Sponsor: | EORTC |
| Recruitment Started: |
Global: 15-Dec-2023 Ireland: 12-Sep-2024 |
| Global Recruitment Target: | 220 |
|---|---|
| Ireland Recruitment Target: | 12 |